Published in Cancer Weekly, August 29th, 2000
Based on the data, published in a recent issue of The Lancet, clinical investigators at the University of Arkansas for Medical Sciences have concluded that additional studies of Thalomid in combination with irinotecan are warranted.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.